Studies using the anti-idiotypic monoclonal antibody 105AD7 in patients with primary and advanced colorectal cancer

Annals of the Royal College of Surgeons of England

Volumn 84, Issue 5, 2002, Pages 314-318

  Maxwell Armstrong, Charles A ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

105AD7; Anti idiotypic antibody; Colorectal cancer; Immunotherapy

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; EDRECOLOMAB; MONOCLONAL ANTIBODY 105AD7; PLACEBO; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; CANCER CELL; CANCER MORTALITY; CANCER SURVIVAL; CASE STUDY; CELL KILLING; CELL STIMULATION; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MINIMAL RESIDUAL DISEASE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TOXICITY;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; APOPTOSIS; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 0036741103     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: 10.1308/003588402760452402     Document Type: Review

References (46)

1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas with a report of 10 original cases. Am J Med Sci 1893; 105: 487-511.
2. Besredka T. Du role de la peau dans la sarcomatose de la souris. Ann Inst Pasteur 1935; 55: 402-16.
3. Falk RE, MacGregor AB, Landi S et al. Immunostimulation with intraperitoneally administered Bacille Calmette Guérin for advanced malignant tumours of the gastrointestinal tract. Surg Gynecol Obstet 1976; 142: 363-8.
4. Buzzi S, Baccini C, Rubboli D. Immunological effects of a boiled diphtheria toxoid on high risk cancer patients. Proc Am Assoc Cancer Res 1997; 38: 397.
5. Chlebowski RT, Nystrom S, Rendds R et al. Long term survival following levamisole or placebo or adjuvant treatment of colorectal cancer: a Western Cancer Study Group trial. Oncology 1988; 45: 141-7.
6. Arnand JP, Buyse M, Nordhinga B. Results of an EORTC double-blind randomised clinical trial. Br J Surg 1959; 76: 284-9.
7. Rosenberg SA, Speiss P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumour-infiltrating lymphocytes. Science 1986; 233: 1318-21.
8. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2, or high dose interleukin-2 alone. N Engl J Med 1987; 316: 889-97.
9. Rosenberg SA. The development of new immunotherapies for the treatment of cancer using interleukin-2. Ann Surg 1988; 208: 121-135.
10. Rosenberg SA, Lotze MT, Yang JC. Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474-85.
11. Maxwell-Armstrong CA, Durrant LG, Scholefield JH. Colorectal cancer vaccines. Br J Surg 1998; 85: 149-54.
12. Maxwell-Armstrong CA, Durrant LG, Scholefield JH. Immune treatment for colorectal cancer. Rec Adv Surg 1998; 21: 97-111.
13. Maxwell-Armstrong CA, Durrant LG, Scholefield JH. The immunotherapy of colorectal cancer. Am J Surg 1999; 177: 344-8.
14. Maxwell-Armstrong CA, Scholefield JH. Current perspectives on immunotherapy for colorectal cancer. Drugs Today 2000; 36: 201-13.
15. Austin EB, Robins RA, Durrant LG et al. Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. Immunology 1989; 67: 525-30.
16. Spendlove I, Li L, Carmichael J et al. Decay accelerating factor (CD55): a target for cancer vaccines. Cancer Res 1999; 59: 2282-6.
17. Austin EB, Robins RA, Baldwin RW et al. Induction of delayed hypersensitivity to human tumour cells with a human monoclonal anti-idiotypic antibody. J Natl Cancer Inst 1991; 83: 1245-8.
18. Denton GWL, Durrant LG, Hardcastle JD et al. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer 1994; 57: 10-4.
19. Maxwell-Armstrong CA, Durrant LG, Robins RA et al. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7. Gut 1999, 45: 593-8.
20. Durrant LG, Maxwell-Armstrong CA, Buckley D et al. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Clin Cancer Res 2000; 6: 422-30.
21. Robins RA. T-cell responses at the host-tumour interface. Biochim Biophys Acta 1986; 856: 289-305.
22. Foon KA, Chakraborty M, John WJ, et al. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 1995; 96: 334-42.
23. Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotypic monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 1997; 3: 1267-76.
24. Herlyn D, Lubeck M, Sears H et al. Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody. J Immunol Methods 1985; 85: 27-35.
25. Herlyn D, Ross AH, Koprowski H. Anti-idiotype antibodies bear the internal image of a human tumour antigen. Science 1986; 232: 100-2.
26. Herlyn D, Wettendorf M, Schmoll E et al. Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci USA 1987; 84: 8055-9.
27. Herlyn D, Benden A, Kane M et al. Anti-idiotype cancer vaccines: preclinical and clinical studies. In Vivo 1991; 5: 615-24.
28. Irving F. The cytoplasmic domain of the T-cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 1991; 64: 891-901.
29. Finn OJ, McKolanis JR, Nalesnik MA et al. T-cell defects in advanced breast, pancreatic and colon cancer, and improvements after vaccination with a mucin peptide. Proc Am Assoc Cancer Res 1996; 37: 490.
30. Matsuda M, Petersson M, Lenkei R et al. Alterations in the signal transducing molecules of T-cells and NK cells in colorectal tumour-infiltrating gut mucosal and peripheral blood lymphocytes: correlation with stage of the disease. Int J Cancer 1995; 61: 765-72.
31. Allen C, Hogg N. Elevation of infiltrating mononuclear phagocytes in human colorectal tumors. J Natl Cancer Inst 1987; 78: 465-470.
32. Ebert EC, Brolin RE, Roberts AI. Characterization of activated lymphocytes in colon cancer. Clin Immunol Immunopathol 1989; 50: 72-81.
33. Hakansson L, Adell G, Boeryd B et al. Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas. Br J Cancer 1997; 75: 374-80.
34. Hutter C. The balance of macrophage subsets may be customised at mucosal surfaces. FEMS Microbial Immunol 1992; 105: 309-14.
35. Poulter LW, Janossy G, Power C et al. Immunological/physiological relationships in asthma: potential regulation by lung macrophages. Immunol Today 1994; 15: 258-64.
36. Tormey VJ, Faul J, Leonard C et al. T-cell cytokines may control the balance of functionally distinct macrophage populations. Immunology 1997; 90: 463-9.
37. Buckley TJD, Robins RA, Durrant LG. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7 delays tumour growth by stimulating anti-tumor T-cell responses. Hum Antibod Hybridomas 1995; 6: 68-72.
38. Waldmann TA, Coldman CK, Robb RJ et al. Expression of interleukin-2 receptors on activated human B cells. J Exp Med 1984; 160: 1450-66.
39. Henney CS, Kuribayashi K, Kern D et al: Interleukin-2 augments natural killer cell activity. Nature 1981; 291: 333-8.
40. Trinchieri G, Matsumoto-Kobayashi M, Clark SC et al. Response of resting human peripheral blood natural killer cells to interleukin. J Exp Med 1984; 160: 1147-69.
41. Smith T. The interleukin-2 receptor. Annu Rev Cell Biol 1989; 5: 397-425.
42. Harel-Bellan A, Bertoglio J, Quillet A et al. Interleukin-2 up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation. J Immunol 1986; 136: 2463-9.
43. Amin S, Robins RA, Maxwell-Armstrong CA et al. Vaccine-induced apoptosis: a novel clinical trial end-point? Cancer Res 2000; 60: 3132-6.
44. Durrant LG, Buckley TJD, Denton GWL et al. Enhanced cell-mediated killing in patients immunized with a human monoclonal anti-idiotypic antibody 105AD7. Cancer Res 1994; 54: 4837-40.
45. Maxwell-Armstrong CA, Durrant LG, Buckley TJD et al. Randomised, double-blind, placebo-controlled survival study assessing the efficacy of the anti-idiotypic monoclonal antibody 105AD7 in patients with advanced colorectal cancer. Br J Cancer 2001; 84: 1443-6.
46. Mella J, Datta SN, Biffin A et al. Surgeons follow-up practice after resection of colorectal cancer. Ann R Coll Surg Engl 1997; 79: 206-9.